BOSTON SCIENTIFIC CORP (BSX) Stock Price & Overview
NYSE:BSX • US1011371077
The current stock price of BSX is 69.96 USD. Today BSX is down by -2.7%. In the past month the price decreased by -5.73%. In the past year, price decreased by -26%.
BSX Key Statistics
- Market Cap
- 103.813B
- P/E
- 22.94
- Fwd P/E
- 20.01
- EPS (TTM)
- 3.05
- Dividend Yield
- N/A
BSX Stock Performance
BSX Stock Chart
BSX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is a bad performer in the overall market: 86.91% of all stocks are doing better.
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to BSX. While BSX has a great profitability rating, there are some minor concerns on its financial health.
BSX Earnings
On February 4, 2026 BSX reported an EPS of 0.8 and a revenue of 5.29B. The company beat EPS expectations (1.62% surprise) and missed revenue expectations (-0.88% surprise).
BSX Forecast & Estimates
40 analysts have analysed BSX and the average price target is 107.14 USD. This implies a price increase of 53.14% is expected in the next year compared to the current price of 69.96.
For the next year, analysts expect an EPS growth of 14.65% and a revenue growth 10.94% for BSX
BSX Groups
Sector & Classification
BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 3.05. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.44% | ||
| ROA | 6.64% | ||
| ROE | 11.96% | ||
| Debt/Equity | 0.46 |
BSX Ownership
BSX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.25 | 195.75B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.54 | 175.278B | ||
| SYK | STRYKER CORP | 23.71 | 140.034B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.85 | 48.896B | ||
| IDXX | IDEXX LABORATORIES INC | 40.4 | 48.604B | ||
| BDX | BECTON DICKINSON AND CO | 12.02 | 47.113B | ||
| RMD | RESMED INC | 20.12 | 36.847B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.07 | 34.468B | ||
| DXCM | DEXCOM INC | 26.66 | 26.455B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.82 | 18.25B | ||
| PODD | INSULET CORP | 36.85 | 16.923B | ||
| HOLX | HOLOGIC INC | 15.39 | 16.875B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
IPO: 1992-05-19
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 53000
Phone: 13026365400
BOSTON SCIENTIFIC CORP / BSX FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX is 69.96 USD. The price decreased by -2.7% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX does not pay a dividend.
What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?
BSX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the employee count for BSX stock?
BOSTON SCIENTIFIC CORP (BSX) currently has 53000 employees.
What is the Short Interest ratio of BOSTON SCIENTIFIC CORP (BSX) stock?
The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 1.8% of its float.